Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Meta Expands AI Training With Employee Activity Tracking Tools 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
EXTON, Pa., March 03, 2016 -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases affecting the skin, connective tissue and joints, will report financial results for the fourth quarter and year ended December 31, 2015 and recent operational highlights on Thursday, March 10, 2016, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EST on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 855-877-0343 (domestic) or +1-678-509-8772 (international), and provide the conference code 47056115 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call. Please visit Fibrocell's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell’s most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for diseases of the skin, connective tissue and joints using genetically-modified autologous fibroblasts. Fibrocell is in pre-clinical development of FCX-007, its orphan gene-therapy product candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in pre-clinical development of FCX-013, its gene-therapy product candidate for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon are in collaboration to develop a gene therapy for the treatment of arthritis. For more information, visit www.fibrocell.com.
Investor Relations Contact: John Woolford Westwicke Partners 443.213.0506 [email protected] Media Relations Contact: Michael Parks 484.356.7105 [email protected]
